Status: Not yet recruiting
Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.
Participants needed: 60
Trial details
Phase: Phase 2Age: 60-85Biological sex: AllType: InterventionalSponsor: TNF Pharmaceuticals, Inc.Updated: Apr 24, 2025
Eligibility criteria
Age 60 to 85 years of age [+9]
Receiving immunotherapy for cancer or solid organ transplantation [+14]